COMP <GO>
SYRE vs UNH // PIOTROSKI F-SCORE QUALITY
Spyre Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: SYRE 4
— UNH 6
▲ PIOTROSKI F-SCORE QUALITY LEADER: UNH
LAST: $95.51 (-1.09%) • MKT CAP: $9.97B
piotroski-score
5/9
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SYRE VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SYRE | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.31% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.00% | 12.38% | -32.38 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.64% | 6.25% | -7.89 | UNH | /fcf-yield <GO> |
| Operating Margin | — | 5.32% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 3.53% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 17.60% | 3.33% | +14.27 | SYRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.09 | +22.91 | SYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.4 | 55.1 | +0.30 | SYRE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.33 | +0.56 | SYRE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 17.7x | +4.26 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.97B | $359.43B | -$349.46B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SYRE REV | UNH REV | SYRE GROSS % | UNH GROSS % | SYRE FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $586.8M | $447.57B | — | 88.7% | -$169.3M | $16.07B |
| FY 2024 | $584.0M | $400.28B | — | 88.3% | -$157.4M | $20.70B |
| FY 2023 | $886.0K | $371.62B | — | 89.6% | -$99.9M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SYRE // BETA 0.89
UNH // BETA 0.33